Antidepressant taken by millions recalled over possible contamination with cancer-causing chemical

A widely prescribed antidepressant, duloxetine delayed-release capsules, faces a significant voluntary recall by distributor Breckenridge Pharmaceuticals after federal regulators detected levels of a probable cancer-causing chemical, N-nitroso-duloxetine, exceeding safe thresholds. This urgent action impacts nearly 375,000 bottles of both 30mg and 60mg doses, forcing millions of patients to re-evaluate their medication regimens and raising fresh alarms over pharmaceutical manufacturing oversight. The contamination is a stark reminder of the persistent challenge nitrosamine impurities pose to the global pharmaceutical supply chain, echoing prior widespread recalls of blood pressure medications like Valsartan and heartburn drugs such as ranitidine (Zantac) in recent years. The FDA has classified this as a Class II recall, signaling a remote probability of serious health consequences, but this isn't duloxetine's first encounter with nitrosamine concerns, with a similar recall occurring in 2024. This recurring issue underscores systemic vulnerabilities in quality control and the need for more robust preventative measures across the industry. Patients currently taking duloxetine are strongly advised not to discontinue their medication abruptly due to potential withdrawal symptoms but should consult their healthcare providers immediately to discuss alternative treatments. Pharmacists nationwide are now tasked with identifying and managing the affected lots, with expiration dates extending into May 2027, as regulatory bodies continue to investigate the root cause of these pervasive contamination events.